# Second-line Immunotherapy for ES-SCLC

> **NCT06853678** · NA · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer (ES-SCLC)

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** Selinexor
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT06853678
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2026-07-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06853678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06853678, "Second-line Immunotherapy for ES-SCLC". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06853678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*